Cori Gorman, PhD MBA

Dr. Gorman is an experienced entrepreneur and research scientist with experience in business and drug development aspects of biotechnology industry. Cori has assisted clients in forming over 20 alliances in just one two year period. Dr. Gorman has served on grant review committees that target funds to industry for over seven years. Her clients have successfully obtained over $80 million in US government funds using the strategies and advice of Dr. Gorman.

At Genentech, Dr. Gorman played a key role in the development of a number of marketed products including Kogenate, Activase, Herceptin, Xolair, and Raptiva. She also played a role the early stages of Avastin. Based on her work at Genentech, Cori is also recognized as a pioneer in the development of monoclonal antibody therapeutics and has co-authored 6 INDs.

An experienced entrepreneur, Cori has worked in all aspects of Start-up Company, including raising capital, strategic planning, recruiting scientists, and developing infrastructure. Her contributions were key to enabling Valentis, a gene therapy company, to proceed to a successful IPO. Dr. Gorman has a strong publication and presentation record and is an inventor on several issued patents in the fields of gene expression and delivery and gene therapy.

Dr. Cori Gorman, who is a partner in the firm DNA Bridges, Inc., is a recognized expert in the biotechnology industry having 16 years experience in this field as a research scientist and administrator. Her experience in strategic planning includes work in genomics, functional genomics and microarray screening; vaccine development, including DNA vaccines; tools for gene targeting and persistent gene expression; cancer; cell biology and neurobiology. She has an outstanding record of achievement in basic research and drug development applications in diverse areas including gene therapy, gene expression, and transfer, hormone processing, cell biology, protein transport, and the humanization and production of recombination of proteins. Two projects have resulted in marketed therapeutics and four projects have therapeutics currently in clinical trials. Dr. Gorman has worked for such industry leaders as Genentech while also being experienced in all aspects of a start-up company. She has a strong publication (over 13,000 citations and 6 classic citations) and presentation record. Dr. Gorman developed the CAT assay in 1980 as a postdoctoral fellow in the LMB/NCI. This assay was developed as a sensitive determiner of gene expression and was the industry standard for over more than fifteen years.

PATENTS

SELECTED PUBLICATIONS

** indicates a classic citation as deemed by Science Citations

Gorman, CM and Bullock C. (2000) Site-specific integration techniques for achieving sustained gene expression. Current Opinion in Biotechnology in press.

Bullock C. and Gorman, CM. (2000) CAT as a reporter. Methods in Enzymoogy, in press

McClarrinon, M, Gilkey,L, Watral, V, Fox, B, Bullock, C, Fradkin, L, Liggitt, D, Roche, L, Bussey, LB and Gorman, CM (1999) Transient transgenesis using lipid-DNA delivery. DNA & Cell Biology DNA Cell Biology. 18:533-547.

Gorman, CM (1998) Aerosol delivery of lipid:DNA complexes to lung of Rhesus monkey. Pharm. Res . 15:671-679.

Gorman, CM, Aikawa, M., Fox, B., Fox, E., Lapuz, C., Michaud, B., Nguyen, H., Roche, E., Sawa, T and Weiner-Kronish, JP (1997) Efficient in vivo delivery of DNA to pulmonary cells using the novel lipid EDMPC. Gene Therapy 4:983- 992.

Pietras Richard J, Arboleda Jane, Reese David M Wongvipat Nancy, Pegram Mark D Ramos Lillian, Gorman, CM,  Parker Malcolm G, Sliwkowski Mark X, Slamon Dennis J. (1995) HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10:2435-2446.

Presta L, Shields R, O'Connell L, Lahr S, Porter J, Gorman CM, Jardieu P. (1994) The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem 269:26368-26373.

Matthews David J, Goodman Laurie J, Gorman, CM, Wells James A. (1994) A Survey of furin substrate specifically using substrate phage display. Protein structure Functions. Protein Science 3:1197-1205.

Goodman Laurie J, Gorman, CM. (1994) Autoproteolytic activation of the mouse prohormone convertase MPC1. BBRC 201:795-804.

Groskreutz D, Sliwkowski M, Gorman, CM. (1994) Constitutive secretion of active insulin by epithelial cells. JBC 269:6241-6245.

Presta L G, Lahr S J, Shields R L, Porter J P, Gorman, CM, Fendly B M, Jardieu P M. (1993) Humanization of an antibody directed against IgE. Journal of Immunology 151(5):2623-2632.

Marriot D, Gillece-Castro B, Gorman, CM (1992) Prohormone Convertase-1 will process pro-relaxin, a member of the insulin family of hormones. Mol. Endo. 6:1441-1450.

Schmelzer C H, Burton L E, Chan W-P, Martin E, Gorman, CM, Canova-Davis E, Ling V T, Sliwkowski M B, McCray G, Briggs J A, Nguyen T H, Polastri G. (1992) Biochemical characterization of recombinant human nerve growth factor. J. of Neurochem. 59:1675-1683.

Carter P. Presta L, Gorman,  CM, Ridgway J, Henner D, Wong W, Rowland A, Kotts C, Carver M, Sheppard M. (1992) Humanization of an anti-p 185 Her2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. 89:4285-4289.

Paborsky L, Caras I, Fisher K, Gorman,  CM. (1991) Lipid association, but not the transmembrane domain, is required for tissue factor activity. J. Biol. Chem. 226:21911-21916.

Choi T, Huang M, Gorman, CM, Jaenisch R. (1991) A generic intron increases gene expression in transgenic mice. Mol. and Cell. Biol. 11:3070-3074.

Gorman, CM. (1990) Mammalian cell expression. Current Opinion in Biotechnology 1:36-47.

Paborsky L. Fendly B M, Fisher K, Lawn R, Marks B J, McCray G, Tate K, Vehar G, Gorman, CM. (1990) Mammalian cell transient expression of tissue factor for the production of antigen. Protein engineering 3 (6):547-553.

Huang M, Gorman, CM. (1990) The simian virus 40 small t intron, present in many common expression vectors, leads to aberrant splicing. Molecular Cell Biology 10(4):1805-1810.

** Gorman, CM, Gies D, McCray G. (1990) Transient production of proteins using adenovirus transformed cell line. DNA protein engineering techniques 2 (1):3-10.

Huang M, Gorman, CM. (1990) Intervening sequence increases efficiency of RNA 3' processing and accumulation of cytoplasmic RNA.  Nucleic Acids Reg. 18(4):937-47.

** Pritchett D B, Sontheimer H, Gorman, CM, Kettenmann H, Seeburg P, Schofield P. (1988) Ligand-gating and allosteric potentiation of human GABA receptor subunits in a transient mammalian cell expression system. Science 242:1306-1308.

Eaton D L, Wood W, Eaton D, Hass P, Hollingshead P, Wion K, Mather J, Lawn R, Vehar G, Gorman, CM. (1986) Construction and characterization of an active Factor VIII variant lacking the central one-third of the Molecule. Biochemistry 25:8343-8347.

** Gorman, CM, Rigby P W J, Lane D P. (1985) Negative regulation of viral enhancers in undifferentiated embryonic stem cells. Cell 42:519-526.

** Gorman, CM. (1985) High efficiency gene transfer. DNA Cloning a Practical Approach. ed. Glover D M, IRL Press.

Gorman, CM, Lane D P, Rigby PW J. (1984) High efficiency gene transfer into mammalian cells. Phil. Trans. R. Soc. Lond. B307:343-346.

** Gorman, CM, Howard B, Reeves R. (1983) Expression of recombinant plasmids in mammalian cells is enhanced by sodium butyrate. Nucleic Acids Res. 11:7631.

** Gorman, CM, Padmanabhan R, Howard B. (1983) High efficiency DNA-mediated transformation of primate cells. Science 221:551-553.

** Gorman, CM, Merlino G, Willingham M, Pastan I, Howard B. (1982) The Rous sarcoma virus LTR is a strong promoter in a variety of cell types when introduced by DNA mediated transfection. Proc. Natl. Acad. Sci. USA 79:6777-6781

**Laimons L, Khoury G, Gorman, CM, Howard B, Gruss P. (1982) Host specific activation of transcription by tandem repeats from SV40 and Maloney sarcoma virus. Proc. Natl. Acad. Sci. USA 79:6453-6457.

** Gorman, CM, Moffat L, Howard B. (1982) Recombinant genomes that express chloramphenicol acetyltransferase in mammalian cells. Mol. Cell. Biol. 2:1044-1051.

HONORS